Bioo Scientific Secures Patent for Using Type 1 Ribosome Inactivating Proteins as Therapeutic Agents

Austin, TX, August 03, 2014 --( Bioo Scientific announced today that the U.S. Patent and Trademark Office (PTO) has issued Patent 8,715,676, “Production and Uses of Type 1 Ribosome Inactivating Proteins”, on May 6, 2014. The newly issued patent describes the use of recombinant type 1 ribosome inactivating proteins as a therapeutic agent to treat cancer and infectious diseases.

In mouse xenograft models, in which human lung tumor cells are implanted in mice, treatment with the patented compound leads to dramatic reduction in tumor burden. In some cases, advanced tumors were shown to completely disappear. Interest in the therapeutic compound, which in its natural form is derived from certain plants, was initially sparked by reports of its use in Chinese medicine to treat malignancy. Scientists at Bioo Scientific successfully cloned, sequenced, and expressed the recombinant protein, and made modifications that facilitate delivery of the drug.

"We believe the recombinant type 1 ribosome inactivating proteins covered by these issued claims offer significant potential for future therapeutic applications," said Dr. Lance Ford, Vice President of Research and Business Development. "Our growing patent portfolio is a reflection of our desire to develop therapeutics to treat various diseases."

Bioo Therapeutics, a division of Bioo Scientific, is seeking corporate partners to help translate its findings into clinical use for treatment of malignancy in humans and animals. Interested parties may contact Dr. Lance Ford at

About Bioo Therapeutics
Bioo Therapeutics (, a division of an Austin, TX based biotechnology company, Bioo Scientific (, was launched in 2009 to leverage Bioo Scientific’s proprietary drug delivery vehicles and extensive experience in antibody and small molecule research to use as a basis to develop therapeutic agents to combat cancer and other diseases. Currently Bioo Therapeutics has several drug candidates in its drug pipeline and a patent-pending drug delivery technology.

Our flagship drug delivery technology is an antibody conjugate which is designed to deliver small RNA drugs into target organs. We have made significant strides in developing and using antibody-based agents for the directed delivery of short interfering RNAs by improving the loading capacity of antibody drug carriers and demonstrating their ability to successfully deliver small RNAs into tumors generated from cells expressing the cell surface target. This research is being supported by funding from the National Science Foundation and the National Institute of Allergy and Disease.

Bioo Therapeutics is seeking funding from outside investors, grants and business partners to support the preclinical and clinical studies of our drug candidates.
Bioo Scientific
Dawn Obermoeller